Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

FLAG-Based Regimen Delivers Strong Outcomes in Subtype of Acute Myeloid Leukemia

A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that combination therapy consisting of fludarabine, cytarabine and G-CSF (FLAG) plus gemtuzumab ozogamicin (GO) or idarubicin (IDA) continues to deliver strong long-term outcomes for patients with core-binding factor acute myeloid leukemia (CBF-AML), a subtype of the disease involving a chromosomal rearrangement.

April 23, 2026


April 23 2026

April 22 2026

April 21 2026

April 20 2026

April 19 2026

April 18 2026

April 17 2026

April 16 2026

April 15 2026

April 14 2026

April 13 2026

April 12 2026

April 11 2026

April 10 2026